Robert W Robey, Christina M Fitzsimmons, Wilfried M Guiblet, William J E Frye, José M González Dalmasy, Li Wang, Drake A Russell, Lyn M Huff, Andrew J Perciaccante, Fatima Ali-Rahmani, Crystal C Lipsey, Heidi M Wade, Allison V Mitchell, Siddhardha S Maligireddy, David Terrero, Donna Butcher, Elijah F Edmondson, Lisa M Jenkins, Tatiana Nikitina, Victor B Zhurkin, Amit K Tiwari, Anthony D Piscopio, Rheem A Totah, Susan E Bates, H Efsun Arda, Michael M Gottesman, Pedro J Batista
Histone deacetylase inhibitors (HDACis) are part of a growing class of epigenetic therapies used for the treatment of cancer. Although HDACis are effective in the treatment of T-cell lymphomas, treatment of solid tumors with this class of drugs has not been successful. Overexpression of the multidrug resistance protein P-glycoprotein (P-gp), encoded by ABCB1, is known to confer resistance to the HDACi romidepsin in vitro, yet increased ABCB1 expression has not been associated with resistance in patients, suggesting that other mechanisms of resistance arise in the clinic...
December 28, 2023: Molecular Cancer Therapeutics